

2020 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Dallas, TX – October 3, 2020

Conference Location	Embassy Suites Dallas Park Central 13131 North Central Expressway Dallas, Texas	Phone: (972) 234-3300 https://embassysuites3.hilton.com/en/hotels/tex-embassy-suites-by-hilton-dallas-park-central-area-DALTXES/index.html
Parking at the Conference	Parking for all participants is complimentary	
Driving Directions	From I-635 East or West: - Take Hwy 75 North to Exit #22 Spring Valley, make a U-Turn and follow the service road about 1.5 miles to the hotel entrance. - Hotel will be located on the right. From Hwy 75 (Traveling South) - Exit #22A Frontage Road and follow the service road to the hotel entrance. - Hotel will be located on the right	
Seminar Agenda and Syllabus Information	Registration and breakfast begin at 7:30 a.m. in the Mesquite Room. Please check signage for any last minute room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. WiFi will be available without charge.	
7:30 am	Registration, Continental Breakfast & View Exhibits	
8:00 am	Opening Comments and Pre-Test	
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant - Staging, workup, and diagnosis of cirrhosis - Medical care of the patient with end stage liver disease Liver Transplantation - Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy	
9:25 am	Hepatocellular Carcinoma (HCC) - Screening diagnostic serum assays and imaging tests - Diagnosis without histology - Treatment and management options: Ablation, TACE and Surgery	
10:00 am	Break & View Exhibits	
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options - Current FDA-Approved Therapies - New chemotherapy regimens in development and testing - Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma	
11:00 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis - Epidemiology of PSC and Ursodiol and Antibiotic Treatments - Predicting outcomes and Improving Survival in PSC patients	

	• Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
11:40 am	Hepatology Update I – Viral Hepatitis The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs
12:00 pm	Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C. Hosted by Alexion Pharmaceuticals
12:55pm	Dessert and View Exhibits
1:10pm	Hepatology Updates - Current/Emerging Topics in Liver Disease • Alcoholic Liver Disease, Liver Disease and Pregnancy, Hepatorenal Syndrome
1:40 pm	NAFLD, LAL-D and NASH • Epidemiology, Demographics and Diagnosis • Treatment options for thrombocytopenia; including alternatives to platelet transfusion. • Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	Break & View Exhibits
2:30 pm	NASH Treatments in Practice and in Development • Current therapies for NASH • Life style changes as a therapy • Drugs in clinical development for NASH • Case Study 3 - NASH Diagnosis and Treatment
3:20 pm	Post-test and Wrap-Up
3:40pm	Seminar Adjourns

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1085. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

**Your
Seminar
Faculty**



JACQUELINE O'LEARY, MD, MPH

Dr. Jacqueline O'Leary began her pursuit of research as an undergraduate at Stanford investigating drug development, continued at UCSF where she received an MD with thesis for work in cellular and molecular biology. Following her internal medicine residency at UT Southwestern in Dallas. Dr. O'Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research there at Harvard focused on immunology. Afterward, she completed a Master's in Public Health from the Harvard School of Public Health. These accomplishments make her uniquely poised to translate research findings into clinical care. She has focused her clinical research in transplant hepatology, viral hepatitis, and Acute-on-Chronic Liver Failure and is currently the Chief of Hepatology at the Dallas VA Medical Center.



AMIT SINGAL, MD, MS

Amit Singal, M.D., M.S. is an Associate Professor of Internal Medicine in the Division of Digestive and Liver Diseases at UT Southwestern Medical Center. He is Medical Director of the UT Southwestern Liver Tumor Program and Clinical Chief of Hepatology. Dr. Singal is a native of the Detroit area and completed most of his medical education at the University of Michigan. He earned his medical degree and a Master of Science at the University of Michigan, as well as fellowships in gastroenterology and transplant hepatology. Dr. Singal Completed his internal medicine residency at the University of Washington in Seattle. Dr. Singal is board certified in internal medicine, gastroenterology, and transplant hepatology. He is also a member of the American Gastroenterology Association, the American College of Gastroenterology, the American Association for the Study of Liver Diseases, and the International Liver Cancer Association.



JORDAN MAYBERRY, MPAS, PA-C

Jordan Mayberry, MPAS, PA-C is a Hepatology physician assistant in the Department of Digestive and Liver Disease at UT Southwestern Medical Center in Dallas, Texas. She graduated from UT Southwestern Medical Center in 2012 with a masters in Physician Assistant Studies. Following graduation she completed the AASLD NP/PA Fellowship program in 2013. Ms. Mayberry has worked in liver disease for over 6 years.